



Sage Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 19, 2019

February 5, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 5, 2019-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Tuesday, February 19, 2019 at 8:00 a.m. EST to report its fourth quarter and full year 2018 financial results and to discuss recent business updates.

The live webcast can be accessed on the investor page of Sage's website at investor.sagerx.com. The conference call can be accessed by dialing 1-866-450-8683 (toll-free domestic) or 1-281-542-4847 (international) and using the conference ID 6968949. A replay of the webcast will be available on Sage's website approximately two hours after the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering CNS disorders. Sage's lead product candidate, ZULRESSO™ (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression. For more information, please visit www.sagerx.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190205005132/en/>

Source: Sage Therapeutics

Investor Contact:

Paul Cox
617-299-8377
paul.cox@sagerx.com

Media Contact:

Maureen L. Suda
585-355-1134
maureen.suda@sagerx.com